Dignitana announced that the Hospital de Clinicas in Montevideo, Uruguay has completed the first stage of a two-year investigational study of DigniCap efficacy in women with breast and ovarian cancer led by Dr. Gabriel Krygier, Director of the Department of Oncology at Hospital de Clinicas. Dr. Krygier reports the first phase of the study demonstrated a 79% success rate, with 19 of the 24 patients using DigniCap Delta retaining more than 50% of their hair (65-95%. Additionally, two patients lost 50% of their hair and three patients discontinued treatment due to cold intolerance during the study.

The FDA-cleared DigniCap Scalp Cooling System minimizes hair loss from chemotherapy for cancer patients with solid tumors such as breast, prostate and gynecological cancers.